Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Rated "Hold" by Wall Street Brokerages

Key Points

• Analysts rate Capricor Therapeutics “Hold” on average: Of 11 firms, six issued hold ratings, four rated it a buy, and one rated it a sell. The average 12-month price target is $30.25.
• CAPR opened at $7.75, with a market capitalization of approximately $450.6 million; its shares have traded between $2.96 and $40.37 over the past year.
• The company reported a quarterly loss of $0.70 per share, missing the consensus estimate of a $0.59 loss. Institutional investors own approximately 21.68% of the stock.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has received an average recommendation of "Hold" from the eleven ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $30.25.

Several equities analysts have commented on CAPR shares. JonesTrading downgraded Capricor Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, July 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Capricor Therapeutics in a research report on Friday, September 11th. Maxim Group lowered shares of Capricor Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, July 30th. Alliance Global Partners cut shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 price target on the stock. in a report on Tuesday, July 28th. Finally, Wall Street Zen downgraded shares of Capricor Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $7.75 on Wednesday. The firm has a market capitalization of $450.58 million, a P/E ratio of -3.16 and a beta of 0.61. Capricor Therapeutics has a 1-year low of $2.96 and a 1-year high of $40.37. The company's 50-day moving average is $7.57 and its 200 day moving average is $20.71.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Research analysts anticipate that Capricor Therapeutics will post -1.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Montanova Capital LLC increased its holdings in Capricor Therapeutics by 7.2% during the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company's stock worth $98,554,000 after purchasing an additional 274,184 shares during the period. Bank of America Corp DE lifted its holdings in shares of Capricor Therapeutics by 672.0% in the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company's stock worth $12,631,000 after buying an additional 361,664 shares during the period. SB Capital Management Inc bought a new position in shares of Capricor Therapeutics during the 4th quarter worth $11,544,000. Walleye Capital LLC bought a new position in shares of Capricor Therapeutics during the 1st quarter worth $5,397,000. Finally, Bank of New York Mellon Corp grew its position in shares of Capricor Therapeutics by 10.4% during the 1st quarter. Bank of New York Mellon Corp now owns 130,730 shares of the biotechnology company's stock worth $3,974,000 after buying an additional 12,366 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company's research is based on technologies intended to modulate inflammation, fibrosis and tissue damage, with an emphasis on rare and degenerative conditions.

Capricor's lead investigational product is deramiocel, formerly known as CAP-1002. It is an allogeneic cell therapy derived from cardiosphere-derived cells and is being developed for Duchenne muscular dystrophy, a progressive genetic disorder that causes muscle degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.